Daunorubicin HCl

Catalog No.S3035 Batch:S303503

Print

Technical Data

Formula

C27H29NO10 . HCl

Molecular Weight 563.98 CAS No. 23541-50-6
Solubility (25°C)* In vitro DMSO 100 mg/mL (177.31 mM)
Water 100 mg/mL (177.31 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. Daunorubicin is a topoisomerase II inhibitor that induces apoptosis.
Targets
DNA synthesis [1]
(Cell-free assay)
20 nM(Ki)
In vitro

At drug concentrations that reflect the peak plasma concentration after Daunorubicin administration, the primary mechanism is likely to be through interaction with topoisomerase II, which may be a primary triggering event for growth arrest and/or cell killing through a signalling pathway leading to apoptosis, at least in leukemic cells and thymocytes. The quinone structure permits daunorubicin to act as electron acceptors in reactions mediated by oxoreductive enzymes including cytochrome P450 reductase, NADH dehydrogenase, and xanthine oxidase. At Daunorubicin concentrations exceeding approximately 2–4 μM, free radical mediated toxicity and DNA cross-linking may become evident. Daunorubicin inhibits both DNA and RNA syntheses in HeLa cells over a concentration range of 0.2 through 2 μM. Daunorubicin inhibits both DNA syntheses in Ehrlich ascites tumor cells over a concentration range of 4 μM. Daunorubic triggers apoptosis at concentrations of 0.5 and 1 μM in either HL-60 or U-937 human leukemic cells. [1]

Daunorubicin stimulates ceramide elevation and apoptosis in P388 and U937 cells through de novo synthesis via activation of the enzyme ceramide synthase. [2]

Daunorubicin dose-dependently increases the phosphatidylserine exposure and consequent procoagulant activity of human umbilical vein endothelial cells. Daunorubicin (0.2 mM) significantly enhances the release of endothelial microparticles which are highly procoagulant in human umbilical vein endothelial cells. [3]

Protocol (from reference)

Cell Assay:

[5]

  • Cell lines

    THTC-07 cells

  • Concentrations

    10 µM

  • Incubation Time

    24 h

  • Method

    Cells were treated with various concentrations of drug.

Animal Study:

[6]

  • Animal Models

    Male Sprague–Dawley rats

  • Dosages

    3 mg/kg

  • Administration

    i.v.

Customer Product Validation

, , Leuk Res, 2015, 39(4):435-44.

Data from [Data independently produced by , , J Transl Med, 2016, 14(1):132]

Data from [Data independently produced by , , Mol Cell Biochem, 2017, 434(1-2):25-32]

Selleck's Daunorubicin HCl has been cited by 76 publications

Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AML [ Nat Commun, 2024, 15(1):4739] PubMed: 38834613
CASZ1 upregulates PI3K-AKT-mTOR signaling and promotes T-cell acute lymphoblastic leukemia [ Haematologica, 2024, 109(6):1713-1725] PubMed: 38058200
Daunorubicin induces GLI1‑dependent apoptosis in colorectal cancer cell lines [ Int J Oncol, 2024, 64(6)66] PubMed: 38757343
Chemotherapy-initiated cysteine-rich protein 61 decreases acute B-lymphoblastic leukemia chemosensitivity [ J Cancer Res Clin Oncol, 2024, 150(3):159] PubMed: 38530432
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment [ BMC Pharmacol Toxicol, 2024, 25(1):25] PubMed: 38444002
Immuno-oncological effects of standard anticancer agents and commonly used concomitant drugs: an in vitro assessment [ BMC Pharmacol Toxicol, 2024, 25(1):25] PubMed: 38444002
SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation [ Cell Stem Cell, 2023, 10.1016/j.stem.2023.09.011] PubMed: 37863054
Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations [ Int J Mol Sci, 2023, 24(16)12926] PubMed: 37629110
Transcriptional Response to Standard AML Drugs Identifies Synergistic Combinations [ Int J Mol Sci, 2023, 24(16)12926] PubMed: 37629110
Bone Marrow Microenvironment-Induced Chemoprotection in KMT2A Rearranged Pediatric AML Is Overcome by Azacitidine-Panobinostat Combination [ Cancers (Basel), 2023, 15(12)3112] PubMed: 37370721

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.